MS Speaks

Multiple Sclerosis => TREATMENTS => LEMTRADA (Campath, alemtuzumab) => Topic started by: agate on May 14, 2019, 04:34:57 pm

Title: EMA to restrict use of alemtuzumab pending review
Post by: agate on May 14, 2019, 04:34:57 pm
The concern about stroke risk has prompted the European Medicines Agency to restrict the use of alemtuzumab pending review. From The Lancet (April 27, 2019), "Alemtuzumab to be restricted pending review, says EMA":


https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30935-3/fulltext